Each 1 ml of solution contains 10 mg of Clindamycin (as Clindamycin Hydrochloride) and 8 mg of Metronidazole.
Clindamycin is an antibiotic belonging to the lincosamide group that inhibits bacterial protein synthesis. It binds to the 50S ribosomal subunit, thereby affecting both the transcription and translation processes of the ribosome. Although clindamycin phosphate is inactive in vitro, it is rapidly hydrolyzed in the body to form antibacterially active clindamycin.
Clindamycin has been shown to be active in vitro against the following microorganisms:
Gram-positive aerobes: Staphylococcus aureus, Staphylococcus epidermidis, streptococci (excluding Enterococcus faecalis), and pneumococci.
Anaerobes: Bacteroides spp., Fusobacterium spp., Peptococcus spp., and Peptostreptococcus spp.
Non-spore-forming Gram-positive anaerobic bacilli: Propionibacterium, Eubacterium, and Actinomyces spp.
Metronidazole is a 5-nitroimidazole derivative that is active against anaerobic protozoa and anaerobic bacteria. It also has a radiosensitizing effect on hypoxic tumor cells. Its mechanism of action is thought to involve interference with DNA through metabolites formed by the reduction of its nitro group. The mechanism of action of topical metronidazole in the treatment of rosacea is unknown.
Indications
Clindan M is indicated for the topical treatment of acne vulgaris (particularly nodular or conglobate acne), rosacea, folliculitis, and other skin infections.
It is also used as an adjunctive treatment for seborrheic dermatitis.
